Additional human clinical trials at 7 and 10 billion dosages of the next-generation probiotic are currently under way.
This landmark study represents a major advance in digestive health science, positioning NūGensia as the gold standard for live and stable Akkermansia supplementation.
The clinical trial demonstrated that NūGensia helps to restore regularity, supports gut health and provides significant improvements in abdominal discomfort and bloating.
Results also showed measurable benefits in bowel frequency, stool consistency and gut barrier integrity, along with improvements in digestive-related quality of life (QOL)—including reduced stress, better sleep and enhanced emotional well-being.
By supporting the balance of the gut microbiome, NūGensia promotes overall digestive health and resilience.
“NūGensia is the first 5 billion CFU live stable Akkermansia muciniphila to clinically validate this level of multidimensional gut health support,” said Subhendu Nayak, Director of R&D – Probiotics at Vidya.
“This human trial confirms what we’ve long believed: Akkermansia is a keystone next-generation probiotic strain — but only if you can deliver it alive, in the right dose and in a stable, effective format.”
The success of NūGensia is built on Vidya’s proprietary, patent-pending delivery system, which uses a starch-based protective shell to shield the live Akkermansia muciniphila strain from oxygen exposure during production and storage.
This innovation overcomes a critical challenge that has long limited the viability and commercial potential of Akkermansia as a dietary supplement ingredient.
Dr Thomas Guilliams, Vidya’s Senior Scientific Adviser, cautions: “The market is flooded by Akkermansia products labelled with AFU or TFU enumeration only."
"Consumers are unaware of the important differences between enumeration methods. CFU remains the gold standard for live and viable strains.”
Unlike many Akkermansia products on the market, NūGensia verifies live counts using the CFU gold standard in every batch — ensuring the strain count label claim is accurate.
NūGensia is now available for formulation in digestive and gut health supporting products.